Stock Taper
Sera Prognostics, Inc. develops blood-based biomarker tests, including PreTRM, to predict pregnancy risks and improve outcomes for conditions like preterm birth, preeclampsia, and gestational diabetes.

The PreTRM Test is a blood-based biomarker that predicts early risk of spontaneous preterm birth in asymptomatic singleton pregnancies at 18-20 weeks, enabling personalized interventions to improve maternal and infant outcomes.
Overall rating: C
| PEER | PRICE | |
|---|---|---|
LUCD | $0.77 | COMPARE |
SRZN | $19.02 | COMPARE |
HURA | $2.07 | COMPARE |
APYX | $2.96 | COMPARE |
CGTX | $1.02 | COMPARE |
ONCY | $0.80 | COMPARE |
RPID | $1.17 | COMPARE |
TVGN | $7.50 | COMPARE |